Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Policy / Regulatory

Guangdong Province Releases New Batch of Urgently Needed Drugs and Medical Devices for Greater Bay Area

Fineline Cube Feb 26, 2024

The Medical Products Administration and Health Commission of Guangdong province have released the sixth batch...

Company Deals Digital

Tencent Hands Over Two Former CSIG Employees to Authorities on Embezzlement Allegations

Fineline Cube Feb 26, 2024

Chinese internet conglomerate Tencent has announced via its anti-fraud department’s official channel that former employees...

Company Drug

Sanofi’s Dupixent Receives FDA Priority Review for COPD Indication Extension

Fineline Cube Feb 26, 2024

Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, announced last week that the US Food...

Company Deals

Kexing Pharmaceutical Partners with Yabao to Distribute Generic Nexavar in Ten Countries

Fineline Cube Feb 26, 2024

China-based Kexing Pharmaceutical (SHA: 688136) has entered into an overseas cooperation agreement with fellow domestic...

Policy / Regulatory

Fujian Province Issues Provisional Regulations for Managing Medical Representative Visits

Fineline Cube Feb 26, 2024

The Fujian provincial health commission and medical products administration have jointly issued the “Provisional Regulations...

Company Drug

GenScript’s Subsidiary Legend Biotech Gets CHMP Nod for Carvykti Label Expansion in Multiple Myeloma

Fineline Cube Feb 26, 2024

GenScript Biotech Corporation (HKG: 1548), a China-based Contract Research Organization (CRO), has announced that its...

Company Drug

Celltrion’s Infliximab Biosimilar Shows Promising Long-Term Efficacy and Safety in CD and UC

Fineline Cube Feb 26, 2024

South Korean biopharmaceutical company Celltrion (KRX: 068270) has presented positive long-term efficacy and safety data...

Company Drug

Takeda’s Recombinant Pig FVIII Drug for Acquired Hemophilia A Approved in China

Fineline Cube Feb 26, 2024

The National Medical Products Administration (NMPA) website has indicated that Takeda (TYO: 4502)’s Obizur (susoctocog...

Company Deals

Mabwell Bioscience Cancels Licensing Agreements with Yangtze River Pharma for Two Drug Candidates

Fineline Cube Feb 26, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Drug

Mabwell Bioscience’s Nectin-4 Targeting ADC Earns FDA Fast-Track Designation for Esophageal Cancer

Fineline Cube Feb 26, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Deals

Boehringer-Ingelheim Partners with CBmed to Accelerate First-in-Class Cancer Medicines Development

Fineline Cube Feb 23, 2024

Boehringer-Ingelheim, a German pharmaceutical giant, has entered into a long-term strategic partnership with Austria-based CBmed...

Company Drug

Polpharma Biologics’ Biosimilar Candidate PB016 Shows Comparable Profiles to Takeda’s Entyvio

Fineline Cube Feb 23, 2024

Polish biotechnology firm Polpharma Biologics has announced positive results from a comparability study for its...

Company Drug

Jiangsu Hengrui Receives NMPA Approval for Adjuvant Therapy Clinical Study of Adebrelimab in NSCLC

Fineline Cube Feb 23, 2024

Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a prominent Chinese pharmaceutical company, has received approval...

Company Drug

BioCity Biopharma Achieves Full Enrollment in Phase II Study of SC0062 for IgA Nephropathy

Fineline Cube Feb 23, 2024

BioCity Biopharma, a Chinese biotechnology company, has announced the completion of enrollment for all 120...

Company Drug

Livzon Pharmaceutical Gets CDE Green Light for JP-1366 Reflux Esophagitis Clinical Study

Fineline Cube Feb 23, 2024

Livzon Pharmaceutical Group Inc. (HKG: 1513), a leading Chinese pharmaceutical company, has announced that its...

Company Drug

Hinova Pharmaceuticals’ HP537 Receives CDE Approval for Clinical Study in Hematologic Malignancies

Fineline Cube Feb 23, 2024

Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech company based in Chengdu, has announced that it...

Company Drug

Jiangsu Hengrui’s CD79b Targeting ADC SHR-A1912 Earns FDA Fast-Track Designation for R/R DLBCL

Fineline Cube Feb 23, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that...

Company Medical Device

Rossum Robot’s Intelligent Surgical Robot for Trauma and Spinal Surgery Clears NMPA Approval

Fineline Cube Feb 23, 2024

Rossum Robot, a Beijing-based developer of orthopedic surgical robots specializing in pelvic fracture procedures, has...

Company Drug

AstraZeneca’s Tagrisso Meets PFS Endpoint in Late-Stage NSCLC Trial and Expands FDA Approval

Fineline Cube Feb 23, 2024

AstraZeneca (AZ; NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced that a late-stage trial...

Company Drug

Pfizer’s Velsipity Approved by European Commission for Moderately to Severely Active Ulcerative Colitis

Fineline Cube Feb 22, 2024

The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its S1P...

Posts pagination

1 … 425 426 427 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.